Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: Knowing when to stop;Doses cumulativas de iodo radioativo no tratamento do carcinoma diferenciado de tireoide: Sabendo a hora de parar

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 9, 2010, Pages 807-812

  Martins Filho, Raul ^a   Ward, Laura S ^a   Amorim, Barbara J ^a   Santos, Allan O ^a   de Lima, Mriana C L ^a   Ramos, Celso D ^a   Matos, Patricia S ^a   Assumpção, Lígia V M ^a   Camargo, Edwaldo E ^a   Etchebehere, Elba C S C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cumulative dose; Differentiated thyroid cancer; Radioiodine therapy

Indexed keywords

EID: 79952021914     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302010000900006     Document Type: Article

References (23)

1. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784-91.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-7.
3. Cordioli MI, Canalli MH, Coral MH. Increase incidence of thyroid cancer in Florianopolis, Brazil: comparative study of diagnosed cases in 2000 and 2005. Arq Bras Endocrinol Metabol. 2009;53(4):453-60.
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
5. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53(7):884-7.
6. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008;22(6):989-1007.
7. De Klerk JM, Oyen WJ. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases. Minerva Endocrinol. 2009;34(1):57-69.
8. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-63.
9. Lin JD, Chao TC, Hsueh C, Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol. 2009;16(9):2609-16.
10. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging. 2004;48(1):12-9.
11. Sipos JA, Kloos RT. Iodine-refractory differentiated thyroid cancer: an ominous diagnosis with the potential for a brighter future. Clin Adv Hematol Oncol. 2008;6(10):767-9.
12. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110(7):1451-6.
13. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well--differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):457-80.
14. Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S, et al. The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. PLoS One. 2009;4(1):e4191.
15. Greene FL, Page D, Morrow M, Balch C, Haller D, Fritz A, et al, eds. AJCC Cancer Staging Manual 6th ed. New York: Springer; 2002.
16. Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20(10):1728-35.
17. Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med. 2006;9(3):156-62.
18. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003;24(5):489-95.
19. Ward LS, Assumpção LVM. Thyroid cancer: prognostic factors and treatment. Arq Bras Endo Metab. 2004;48(1):126-36.
20. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
21. Steinmüller T, Klupp J, Rayes N, Ulrich F, Jonas S, Gräf KJ, et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg. 2000;166(1):29-33.
22. Mihailovic J, Stefanovic L, Malesevic M, Markoski B. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Thyroid 2009;19(3):227-32.
23. Zucchelli G, Iervasi A, Ferdeghini M, Iervasi G. Serum thyroglobulin measurement in thefollow-up of patients treated for differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53(5):482-9.